Chemoradiation therapy (CRT) for head and neck cancer is overused at some centers in patients with early-stage laryngeal cancer, and more care should be taken not to overtreat patients with therapy that can have toxic effects, said invited lecturer Jonas Johnson, MD, at the Annual Meeting of the Triological Society, held here on April 29 as part of the Combined Otolaryngology Spring Meetings.
Physicians have noted the potential for dizziness in migraine patients since the 19th century. And yet the 21st century has so far failed to bring any unifying definition to a symptom that is frustratingly diffuse in its intensity and frequency and unclear in its origins.
The idea of reusing single-use devices may bring to mind the recent news of a Las Vegas urologist who was investigated in March for supposedly resuing single-use devices. As the Las Vegas Review-Journal reports, Dr. Michael Kaplan is accussed of reusing, but not not decontaminating, endocavity needle guides. While Dr. Kaplan’s specific case may be unique, the idea of reprocessing single-use devices is not.
Quantitative real-time polymerase chain reaction (Q-PCR) can be a valuable tool in the operating room to determine whether head and neck cancer patients should go on to elective neck dissection, researchers said here on April 29 at the Annual Meeting of the Triological Society, held as part of the Combined Otolaryngology Spring Meetings.
Neurotrophic factors can be introduced using stem cells and, along with the plant alkaloid vincristine, can be used to selectively reinnervate the larynx in rat models, a researcher from Indiana University said here on April 29 at the Annual Meeting of the Triological Society, held as part of the Combined Otolaryngology Spring Meetings.
Surgically releasing specific “trigger sites” may provide long-term relief for some sufferers of chronic migraine. According to a recent study published in Plastic and Reconstructive Surgery, 88 percent of patients who underwent surgical deactivation of targeted trigger sites reported at least a 50 percent reduction in the frequency, severity and duration of their migraine headaches five years later.
When performing certain procedures, many otolaryngologists use succinylcholine, a neuromuscular blocking agent, to help them monitor the facial nerve.
Regarding the article, “Otolaryngologist Pioneers New Practice Model: Dr. Russell heralds hospitalist role as others ponder the concept’s staying power”…
For decades, otolaryngologists have been frustrated by the refusal of some patients with hearing loss to use hearing aids. Statistics on noncompliance vary, but there is general agreement that only about 20 percent to 25 percent of Americans with treatable hearing loss use hearing aids. The problem seems to be more acute for people with mild hearing loss: A consumer survey conducted by the nonprofit Better Hearing Institute in 2009 found that fewer than 10 percent of people with mild hearing loss use amplification and that even among people with moderate-to-severe hearing loss, only four in 10 use amplification.